Tsubota A, Satoh KI, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, Fujise K, Tajiri H. Four-week pegylated interferon α-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study. World J Gastroenterol 2008; 14(47): 7220-7224 [PMID: 19084937 DOI: 10.3748/wjg.14.7220]
Corresponding Author of This Article
Dr. Akihito Tsubota, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan. atsubo@jikei.ac.jp
Article-Type of This Article
Rapid Communication
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tsubota A, Satoh KI, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, Fujise K, Tajiri H. Four-week pegylated interferon α-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study. World J Gastroenterol 2008; 14(47): 7220-7224 [PMID: 19084937 DOI: 10.3748/wjg.14.7220]
Akihito Tsubota, Yoshihisa Namiki, Institute of Clinical Medicine and Research, Jikei University School of Medicine, Chiba 277-8567, Japan
Akihito Tsubota, Ken-ichi Satoh, Mashu Aizawa, Seishi Takamatsu, Toshifumi Ohkusa, Kiyotaka Fujise, Department of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine, Chiba 277-8567, Japan
Hisao Tajiri, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 105-8461, Japan
Author contributions: Tsubota A, Satoh K, Takamatsu S, and Fujise K designed the study; Tsubota A, Satoh K, Aizawa M, Takamatsu S, Ohkusa T, and Fujise K performed research; Tsubota A, Satoh K and Namiki Y analyzed data; and Tsubota A, Fujise K and Tajiri H wrote the paper.
Supported by Clinical Research Funds from Department of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine
Correspondence to: Dr. Akihito Tsubota, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan. atsubo@jikei.ac.jp
Telephone: +81-4-7164-1111 Fax: +81-4-7166-8638
Received: August 13, 2008 Revised: November 18, 2008 Accepted: November 25, 2008 Published online: December 21, 2008
Abstract
AIM: To assess the efficacy and advantages of 4-wk pegylated interferon α-2a (peg-IFN-α2a) monotherapy for chronic hepatitis C patients with strong predictors of sustained virologic response (SVR).
METHODS: Patients (n = 33) with genotype 2 and low viral load (< 100 KIU/mL), who became HCV RNA negative after 1 wk of IFN treatment, were randomly allocated to receive a 4- or 12-wk treatment course at a ratio of 2:1, respectively, with a subsequent 24-wk follow-up period. Peg-IFN-α2a was administered subcutaneously at a dose of 180 μg or 90 μg once weekly. SVR was defined as absence of serum HCV RNA at the end of the follow-up period.
RESULTS: All patients completed the treatment schedule, and more than half were symptom-free during the treatment. In the 4-wk treatment group, 20 of 22 (91%) patients achieved SVR. Two patients relapsed, but achieved SVR following re-treatment with peg-IFN-α2a alone. In the 12-wk treatment group, 11 of 11 (100%) patients attained SVR.
CONCLUSION: Our results show that a 4-wk course of peg-IFN-α2a monotherapy can achieve a high SVR rate in “IFN-sensitive” patients, without negatively affecting outcome.
